ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference
ALX Oncology (Nasdaq: ALXO) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York City. CEO Jason Lettmann will engage in a fireside chat with analyst Christopher Raymond on December 3, 2024, at 9:30 AM EST. The event will also include one-on-one meetings.
The fireside chat will be accessible via webcast through ALX Oncology's website investor section, with a replay available for up to 90 days following the event. ALX Oncology is a clinical-stage biotechnology company focused on developing immune system-boosting cancer therapies to extend patient lives.
ALX Oncology (Nasdaq: ALXO) ha annunciato la sua partecipazione alla 36ª Conferenza Annuale sulla Sanità di Piper Sandler a New York City. Il CEO Jason Lettmann parteciperà a una chiacchierata informale con l'analista Christopher Raymond il 3 dicembre 2024, alle 9:30 AM EST. L'evento includerà anche incontri individuali.
La chiacchierata informale sarà accessibile tramite webcast nella sezione investitori del sito web di ALX Oncology, con una registrazione disponibile per un massimo di 90 giorni dopo l'evento. ALX Oncology è una compagnia biotecnologica in fase clinica focalizzata sullo sviluppo di terapie contro il cancro che potenziano il sistema immunitario per prolungare la vita dei pazienti.
ALX Oncology (Nasdaq: ALXO) ha anunciado su participación en la 36ª Conferencia Anual de Salud de Piper Sandler en Nueva York. El CEO Jason Lettmann participará en una charla junto al analista Christopher Raymond el 3 de diciembre de 2024, a las 9:30 AM EST. El evento también incluirá reuniones individuales.
La charla será accesible a través de un webcast en la sección de inversores del sitio web de ALX Oncology, con una repetición disponible por hasta 90 días después del evento. ALX Oncology es una compañía biotecnológica en etapa clínica enfocada en desarrollar terapias oncológicas que mejoran el sistema inmunológico para extender la vida de los pacientes.
ALX Oncology (Nasdaq: ALXO)는 뉴욕에서 열리는 Piper Sandler 제36회 연례 헬스케어 컨퍼런스에 참석한다고 발표했습니다. CEO Jason Lettmann은 2024년 12월 3일 오전 9시 30분 EST에 애널리스트 Christopher Raymond와 함께 대화할 예정입니다. 이 이벤트는 개별 미팅도 포함됩니다.
대화는 ALX Oncology의 웹사이트 투자자 섹션을 통해 웹캐스트로 제공되며, 이벤트 후 최대 90일 동안 다시 볼 수 있습니다. ALX Oncology는 환자의 생명을 연장하기 위해 면역계 강화를 목표로 한 항암 치료법 개발에 집중하는 임상 단계의 생명공학 회사입니다.
ALX Oncology (Nasdaq: ALXO) a annoncé sa participation à la 36e Conférence Annuelle sur la Santé de Piper Sandler à New York. Le PDG Jason Lettmann participera à une discussion informelle avec l'analyste Christopher Raymond le 3 décembre 2024 à 9h30 EST. L'événement inclura également des réunions individuelles.
La discussion informelle sera accessible via un webdiffusion sur la section investisseurs du site Web d'ALX Oncology, avec une rediffusion disponible jusqu'à 90 jours après l'événement. ALX Oncology est une entreprise de biotechnologie en phase clinique axée sur le développement de thérapies anticancéreuses qui renforcent le système immunitaire pour prolonger la vie des patients.
ALX Oncology (Nasdaq: ALXO) hat seine Teilnahme an der 36. jährlichen Healthcare-Konferenz von Piper Sandler in New York City bekannt gegeben. CEO Jason Lettmann wird am 3. Dezember 2024 um 9:30 Uhr EST in einem informellen Gespräch mit Analyst Christopher Raymond teilnehmen. Die Veranstaltung umfasst auch Einzelgespräche.
Das informelle Gespräch wird über ein Webcast im Investorenbereich der Website von ALX Oncology zugänglich sein, mit einem Replay, das bis zu 90 Tage nach der Veranstaltung verfügbar ist. ALX Oncology ist ein biotechnologisches Unternehmen in klinischer Phase, das sich auf die Entwicklung von krebsbekämpfenden Therapien konzentriert, die das Immunsystem stärken, um das Leben der Patienten zu verlängern.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives, today announced that Jason Lettmann, the Company’s Chief Executive Officer will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference being held in New York City from December 3-5, 2024.
Format: Fireside chat with analyst, Christopher Raymond and 1x1 meetings
Date: Tuesday, December 3, 2024
Time: 9:30 AM EST
Location: New York City, NY
Webcast link: Available here
The live webcast for the Piper Sandler fireside chat can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com and selecting Events under the News and Events tab. A replay of the webcast will be archived for up to 90 days following the fireside chat date.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
FAQ
When is ALX Oncology (ALXO) presenting at the Piper Sandler Healthcare Conference 2024?
How can I watch ALX Oncology's (ALXO) Piper Sandler Conference presentation?
How long will ALX Oncology's (ALXO) Piper Sandler Conference webcast be available?
What type of presentation will ALX Oncology (ALXO) give at the Piper Sandler Conference?
